Biotechnology
BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention
BOSTON, June 9, 2022 /PRNewswire/ -- BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give a company presentation onJune 16, 12:00 at BIO International convention, taking place inSan Diego, California, between June 13-16, 2022. BIORCEHSTRA's company presentation will cover its lead therapeut...
2022-06-09 20:30
2559
Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board
Promising 'dark matter' cancer therapy has clinical trials in sight DUNEDIN, New Zealand, June 8, 2022 /PRNewswire/ -- Amaroq Therapeutics, a biotechnology company focussed on developing a new class of therapeutics that target lncRNA in cancer, is progressing towards clinical trials following a ...
2022-06-09 00:05
2512
OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate
NEW YORK, June 8, 2022 /PRNewswire/ -- OnCusp Therapeutics announced today a licensing agreement with Multitude Therapeutics for the development and commercialization of AMT-707 (now referred to as CUSP06), a potentially highly differentiated second-in-class CDH6 antibody drug conjugate ("ADC"). ...
2022-06-08 20:00
2202
The 3rd BIO International Convention 2022 is Approaching
SAN DIEGO, June 7, 2022 /PRNewswire/ -- With the 3rd BIO International Convention 2022 soon approaching, Neurophth Therapeutics is looking forward to discussing collaboration opportunities in gene therapy for both rare and common ocular diseases. Neurophth Therapeutics is a leading clinical-stag...
2022-06-07 19:23
2379
PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT
SYDNEY, June 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II, genomically-guided study of multiple therapies in patients with brain metastases, led by the Alliance for Clinical Trials in Oncology (NC...
2022-06-07 19:00
2908
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
KANAGAWA, Japan, June 7, 2022 /PRNewswire/ -- Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-...
2022-06-07 14:00
2018
iNtRON Completes GLP-TOX Studies of BAL200
* A novel drug candidate for anthrax received orphan drug designation (ODD) by the US FDA. BOSTON and SEOUL, Korea, June 6, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON" or "Company") announced today that the company has successfully completed the GLP toxicology studies of BAL200. The co...
2022-06-07 09:00
2565
Senhwa's Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC
TAIPEI and SAN DIEGO, June 6, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that it has received written approval from the Human Research Ethics Committ...
2022-06-06 21:00
2979
ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022
SHANGHAI, June 6, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that an international randomized phase 3 study (ASTRUM-005) of HANSIZHUANG (serplulimab), an anti-PD-1 mAb independently developed by Henlius, as first-line treatment for extensive-stage small-cell lung can...
2022-06-06 21:00
3017
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
SHANGHAI, June 6, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual M...
2022-06-06 20:50
3626
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...
2022-06-06 12:23
3160
OriCiro Announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology
TOKYO, June 5, 2022 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has closed Series B2 financing from Asahi Kasei Medical Co., Ltd. OriCiro has advanced its busine...
2022-06-06 10:09
2358
Gracell Biotechnologies Schedules Clinical Update Call After EHA2022
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, June. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...
2022-06-03 23:00
6963
KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
SYDNEY, June 3, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The data is the subj...
2022-06-03 19:00
9604
Sanyou Super-Trillion Innovative Antibody Drug Discovery Platform Announced - World Premiere
SHANGHAI, June 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals officially
launched STAL (Super-Trillion Antibody Libraries) onJune 3, 2022, which is a
super-trillion innovative antibody drug discovery platform of Sanyou's own
intellectual property.
2022-06-03 08:00
3059
ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic
- Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into preclinical development and further strengthen/expand innovative technology platforms - Build vertically integrated internal capabilities for more efficient drug development WOODINVILLE, Wash. and SUZHOU, China...
2022-06-02 20:00
3201
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability MELBOURNE, Australia, June 2, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disea...
2022-06-02 20:00
3279
Standigm Signs MOU with Merck Korea for AI drug Discovery Research
- Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Und...
2022-06-01 21:00
3019
Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit
SHANGHAI, June 1, 2022 /PRNewswire/ -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxu...
2022-06-01 19:49
2501
QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings
SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...
2022-05-31 22:30
4010
Week's Top Stories
Most Reposted
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Creality 3D Successfully Listed in Hong Kong
[Picked up by 271 media titles]
2026-05-29 11:21
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
[Picked up by 269 media titles]
2026-05-30 11:58
PHOTO & IMAGE SHANGHAI 2026 to Showcase AI Imaging, Content-Creation Technologies and Emerging Visual Trends This July
[Picked up by 269 media titles]
2026-05-29 17:36
Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
8044
AMTD's Successful Completion of Acquisition of The Ritz-Carlton, Perth, Valued at A$280 Million
2026-05-29 21:50
7487
Creality 3D Successfully Listed in Hong Kong
2026-05-29 11:21
6976
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
2026-05-29 22:00
6635